Alternate-Day Buprenorphine Administration. Phase VIII - 9
3 other identifiers
interventional
N/A
1 country
1
Brief Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 1994
CompletedFirst Submitted
Initial submission to the registry
September 20, 1999
CompletedFirst Posted
Study publicly available on registry
September 21, 1999
CompletedMay 6, 2016
July 1, 1996
September 20, 1999
May 5, 2016
Conditions
Outcome Measures
Primary Outcomes (4)
Drug use
Opioid withdrawal
Opioid agonist effects
Dose choice
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- University of Vermontlead
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
Treatment Research Center
Burlington, Vermont, 05401, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Warren Bickel, Ph.D.
University of Vermont
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 20, 1999
First Posted
September 21, 1999
Study Start
August 1, 1994
Last Updated
May 6, 2016
Record last verified: 1996-07